U.S.-based investment fund Mason Capital said on Monday it had sent a letter to Spain's stock market regulator CNMV demanding ...

The Michael J. Fox Foundation for Parkinson’s Research has partnered with Grifols, a global healthcare company, to identify ...

The family that owns Spanish drugmaker Grifols and private equity firm Brookfield are considering whether to take the company private in a deal that could be worth around €5.5 billion (almost $6 ...

Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to ...

Flat Footed is the largest non-Grifols family Class A shareholder of the Company. We appreciate the Grifols Board of Directors’ (the “Board”) recent appointment of Paul Herendeen as an ...

Private equity company Brookfield has reportedly moved closer to taking control of Grifols, after months of disruption at the Spanish pharma company. A report in Spanish newspaper El Confidencial ...

Mason Capital Management LLC’s Kenneth M Garschina has called the Spanish regulator’s attention to Grifols SA’s “severe lack of disclosure” as he tries to push for a board reshuffle.

(Bloomberg) -- Grifols SA sued Gotham City Research over a report alleging the company has overstated profit and misstated its accounting. Gotham City Research, run by Daniel Yu and Cyrus de Weck ...

On Wednesday, Grifols SA (NASDAQ:GRFS) said it ended discussions with Brookfield Capital Partners (UK) Limited about a potential acquisition. This decision follows the company’s November 19 ...

The Catalan blood products company has received a $21 million grant from the Michael J. Fox Foundation (MJFF) for Parkinson's ...

Grifols, S.A. (NASDAQ:GRFS – Get Free Report)’s share price dropped 2.7% during trading on Friday .The company traded as low as $7.48 and last traded at $7.51. Approximately 203,161 shares ...

The unique plasma assets serve as the foundation of the Chronos-PD program, driving advanced research at Grifols subsidiary Alkahest, which is leading the initiative given its specialization in the ...